Asia-Pacific Next Generation Sequencing (NGS) In Cancer Diagnostics Market is expected to grow with the CAGR of 21.9% in the forecast period of 2020 to 2027. The years considered for study are as mentioned below.
Asia-Pacific next generation sequencing (NGS) in cancer diagnostics market is a highly consolidated market, which includes specific number of key players. The market has witnessed increased strategic developments owing to favourable market scenario.
The major players dealing in Asia-Pacific next generation sequencing (NGS) in cancer diagnostics market are introducing strong range of products provider along with launching new products and adopting strategic initiative such as acquisition, agreement into the market. This helped companies to maximize the sales with enhanced product portfolio. For instance, in May 2020, ArcherDX, Inc. collaborated with Bayer in order to develop the companion diagnostic (CDx) for Vitrakvi (larotrectinib) which utilize the next generation sequencing technology (NGS). This collaboration done by the company will strengthen its cancer diagnostics segment in the market.
Agilent Technologies, Inc.is the dominating player in Asia-Pacific next generation sequencing (NGS) in cancer diagnostics market. The other key players existing in the market includes Twist Bioscience, Millennium Science Pty Ltd, Dow Biomedica Co., Spinco Biotech Pvt Ltd, Quantabio, Swift Biosciences Inc., ArcherDX, Inc., Premas Life Sciences and TOMY DIGITAL BIOLOGY CO., LTD., among others.
Agilent Technologies, Inc. incorporated in 1999, headquarters in California, U.S. The company is engaged in providing laboratories across globe with instruments, services, consumables, applications and expertise. The company is associated with life sciences, diagnostics and applied chemical markets The company is providing products under analytical instruments and supplies, life science, clinical & diagnostic testing, lab management & consulting, lab supplies, lab automation, lab software, dissolution testing, vacuum & leak detection product categories. The market focus products lie under life science product category. The company is engaged in continuous distribution of the next generation sequencing (NGS) in cancer diagnostic.
The company has a wide presence across Asia-Pacific, Europe, North America and South America. The company has various subsidiaries like Agilent Technologies Rhone AG (Switzerland), AT Singapore (Global) Pte Ltd (Singapore), Agilent Technologies World Trade, Inc (U.S.), Agilent Technologies Singapore (Holding) Pte. Ltd.(Singapore) and Agilent Technologies Singapore (International) Pte. Ltd. (Singapore), among others.
TOMY DIGITAL BIOLOGY CO., LTD.
TOMY DIGITAL BIOLOGY CO.,LTD headquartered in Tokyo, Japan was founded in 1958. The company focuses on providing high quality instruments and superior services to customers across various industry segments, including biotechnology, biological engineering, medical science and food development. The company is providing products under manufactured products and allianced products. The market focus products lie under allianced product category. The company has initiated many strategic initiatives to expand its market.
The company has a wide presence across Asia-Pacific. The company also has various subsidiary companies such as TOMY SEIKO CO.,LTD. (Japan), TOMY KOGYO CO., LTD. (Japan), TOMY MANAGEMENT SERVICE CO., LTD. (Japan), TOMY MEDICO CO., LTD. (Japan) and TOMY OKINAWA NOVO SCIENCE CO., LTD. (Japan).
Twist Bioscience was incorporated in 2013. The company focuses in synthetic biology and has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company is engaged in providing products in categories like SARS-COV-2 tools, genes, oligo pools, variant libraries, DNA data storage, NGS and biopharma among which NGS is the market focused category.
The company has a wide presence across North America, Europe, Middle East & Africa and Asia-Pacific. The company has various subsidiary companies such as Twist Bioscience Worldwide (Cayman Islands), Twist Bioscience Israel Ltd (Israel), Twist Bio Computing, LLC (U.S.), Twist Pharmaceutical Solutions, LLC (U.S.) and Twist Bioscience Singapore PTE. LTD. (Singapore) among others. The company has initiated many strategic initiatives to expand its market.